scholarly journals Fight them or feed them: how the intestinal mucus layer manages the gut microbiota

2019 ◽  
Vol 7 (1) ◽  
pp. 3-12 ◽  
Author(s):  
Bjoern O Schroeder
2013 ◽  
Vol 45 ◽  
pp. S72-S73
Author(s):  
F. Scaldaferri ◽  
L.R. Lopetuso ◽  
V. Petito ◽  
V. Gerardi ◽  
M. Bilotta ◽  
...  

2021 ◽  
Vol 27 (Supplement_1) ◽  
pp. S40-S40
Author(s):  
Melinda Engevik ◽  
Heather Danhof ◽  
Jennifer Auchtung ◽  
Maribeth Nicholson ◽  
Qinglong Wu ◽  
...  

Abstract Background Clostridioides difficile is a common healthcare associated pathogen in U.S. hospitals, incurring billions of dollars in treatment costs each year. Microbiome analysis of C. difficile infected (CDI) patients have revealed alterations of the gut microbiota. It has been speculated that select members of this altered microbiota may influence C. difficile pathogenesis. C. difficile is known to reside in the intestinal mucus layer, but at present the interactions between C. difficile and other mucus-associated bacteria are poorly defined. To address these gaps in knowledge, we have focused on an entirely human-centered approach, employing human-derived MUC2, fecal bioreactors and patient samples. We hypothesized that select mucus-associated bacteria would promote C. difficile colonization and biofilm formation. Methods & Results To create a model of the human intestinal mucus layer and gut microbiota, we developed a bioreactor system with human MUC2-coated coverslips. Bioreactors were inoculated with healthy human feces, treated with clindamycin and infected with C. difficile to mimic CDI. C. difficile was found to colonize and form biofilms on MUC2-coated coverslips and 16S rRNA sequencing revealed a unique biofilm profile with substantial co-colonization with Fusobacterium. Consistent with our bioreactor data, publicly available datasets and patient stool samples revealed that a subset of patients with C. difficile infection harbored high levels of F. nucleatum OTUs. We also isolated microbes from adult patients and pediatric IBD patient stool who were positive for C. difficile and F. nucleatum and identified co-localization between these strains. RNAseq data revealed significant changes in C. difficile chemotaxis and surface adhesion genes following exposure to F. nucleatum metabolites. C. difficile was found to co-aggregate with F. nucleatum; an effect that was inhibited by blocking the Fusobacterial adhesin RadD and C. difficile flagella. Moreover, a ΔradD mutant of F. nucleatum lost the ability to aggregate with C. difficile. Conversely, removal of flagella from C. difficile significantly reduced the interaction between WT F. nucleatum and C. difficile. Addition of F. nucleatum also enhanced C. difficile biofilm formation, increasing the levels extracellular polysaccharide. Conclusions Collectively, these data demonstrate the unique role of mucus-associated bacteria such as F. nucleatum in facilitating colonization of the mucus layer by pathogenic C. difficile.


2013 ◽  
Vol 7 ◽  
pp. S37-S38
Author(s):  
F. Scaldaferri ◽  
L.R. Lopetuso ◽  
V. Petito ◽  
V. Gerardi ◽  
M. Bilotta ◽  
...  

Molecules ◽  
2021 ◽  
Vol 26 (9) ◽  
pp. 2630
Author(s):  
Jiah Yeom ◽  
Seongho Ma ◽  
Jeong-Keun Kim ◽  
Young-Hee Lim

Colitis causes destruction of the intestinal mucus layer and increases intestinal inflammation. The use of antioxidants and anti-inflammatory agents derived from natural sources has been recently highlighted as a new approach for the treatment of colitis. Oxyresveratrol (OXY) is an antioxidant known to have various beneficial effects on human health, such as anti-inflammatory, antibacterial activity, and antiviral activity. The aim of this study was to investigate the therapeutic effect of OXY in rats with dextran sulfate sodium (DSS)-induced acute colitis. OXY ameliorated DSS-induced colitis and repaired damaged intestinal mucosa. OXY downregulated the expression of pro-inflammatory cytokine genes (TNF-α, IL-6, and IL-1β) and chemokine gene MCP-1, while promoting the production of anti-inflammatory cytokine IL-10. OXY treatment also suppressed inflammation via inhibiting cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) expression in the colon, as well as the activity of myeloperoxidase (MPO). OXY exhibited anti-apoptotic effects, shifting the Bax/Bcl-2 balance. In conclusion, OXY might improve DSS-induced colitis by restoring the intestinal mucus layer and reducing inflammation within the intestine.


2020 ◽  
Vol 295 (46) ◽  
pp. 15712-15726
Author(s):  
Bjoern O. Schroeder ◽  
George M. H. Birchenough ◽  
Meenakshi Pradhan ◽  
Elisabeth E. L. Nyström ◽  
Marcus Henricsson ◽  
...  

The intestinal mucus layer is a physical barrier separating the tremendous number of gut bacteria from the host epithelium. Defects in the mucus layer have been linked to metabolic diseases, but previous studies predominantly investigated mucus function during high-caloric/low-fiber dietary interventions, thus making it difficult to separate effects mediated directly through diet quality from potential obesity-dependent effects. As such, we decided to examine mucus function in mouse models with metabolic disease to distinguish these factors. Here we show that, in contrast to their lean littermates, genetically obese (ob/ob) mice have a defective inner colonic mucus layer that is characterized by increased penetrability and a reduced mucus growth rate. Exploiting the coprophagic behavior of mice, we next co-housed ob/ob and lean mice to investigate if the gut microbiota contributed to these phenotypes. Co-housing rescued the defect of the mucus growth rate, whereas mucus penetrability displayed an intermediate phenotype in both mouse groups. Of note, non-obese diabetic mice with high blood glucose levels displayed a healthy colonic mucus barrier, indicating that the mucus defect is obesity- rather than glucose-mediated. Thus, our data suggest that the gut microbiota community of obesity-prone mice may regulate obesity-associated defects in the colonic mucosal barrier, even in the presence of dietary fiber.


2020 ◽  
Vol 3 (5) ◽  
pp. 2897-2909 ◽  
Author(s):  
Abhinav Sharma ◽  
Jun-Goo Kwak ◽  
Kristopher W. Kolewe ◽  
Jessica D. Schiffman ◽  
Neil S. Forbes ◽  
...  

2010 ◽  
Vol 68 (2) ◽  
pp. 279-288 ◽  
Author(s):  
Sharvil U. Sheth ◽  
Qi Lu ◽  
Kate Twelker ◽  
Susan M. Sharpe ◽  
Xiaofa Qin ◽  
...  

Nanoscale ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 2991-2998 ◽  
Author(s):  
Alan Mackie ◽  
Simon Gourcy ◽  
Neil Rigby ◽  
Jonathan Moffat ◽  
Isabel Capron ◽  
...  

The intestinal mucus layer prevents cellulose nanocrystals from reaching the epithelium and can modulate lipid and bile absorption.


2016 ◽  
Vol 37 (1) ◽  
pp. 3-4 ◽  
Author(s):  
Shipra Vaishnava

Sign in / Sign up

Export Citation Format

Share Document